Placebo-controlled cohorta: relative contribution of the secondary ACR components (PGA, PtGA, Pain, HAQ-DI, and CRP) to the overall ACR50 response rates in patients treated with TOF 5 mg BID + csDMARDs, TOF 10 mg BID + csDMARDs, ADA + csDMARDsb, or placebo + csDMARDs at month 3 (FAS).
| TOF 5 mg BID + csDMARDs, N = 737 | TOF 10 mg BID + csDMARDs, N = 738 | ADA + csDMARDs, N = 185 | Placebo + csDMARDs, N = 378 | ||||
|---|---|---|---|---|---|---|---|
| ACR Component (By Rank) | n (%) | ACR Component (By Rank) | n (%) | ACR Component (By Rank) | n (%) | ACR Component (By Rank) | n (%) |
| 1. PGA | 189 (25.6) | 1. PGA | 225 (30.5) | 1. PGA | 30 (16.2) | 1. PGA | 18 (4.8) |
| 2. PtGA | 195 (26.5) | 2. CRP | 226 (30.6) | 2. Pain | 32 (17.3) | 1. PtGA | 18 (4.8) |
| 3. CRP | 196 (26.6) | 3. Pain | 235 (31.8) | 3. CRP | 33 (17.8) | 1. Pain | 18 (4.8) |
| 4. Pain | 198 (26.9) | 4. HAQ-DI | 238 (32.3) | 4. PtGA | 35 (18.9) | 4. HAQ-DI | 28 (7.4) |
| 5. HAQ-DI | 204 (27.7) | 5. PtGA | 241 (32.7) | 5. HAQ-DI | 36 (19.5) | 5. CRP | 29 (7.7) |